The CRISPR/Cas9 gene editing platform has accelerated vaccine development against infectious diseases. Scientists use CRISPR to improve their understanding of host-virus interactions and viral gene functions, screen for vaccine targets, and act as an antiviral agent. In this webinar brought to you by ERS, Rao Venigalla will discuss a novel approach to vaccine development using CRISPR engineering of bacteriophages.
Topics to be covered
- CRISPR engineering; needle-free SARS-CoV-2 vaccine
- A bacteriophage T4-based, highly efficacious, needle and adjuvant-free, mucosal COVID-19 vaccine
Tuesday, May 31st, 2022 | 2:30 - 3:30 PM Eastern Time
This webinar will be available to view live and on demand.
Rao B. Venigalla, PhD
Professor of Biology
Director, Bacteriophage Medical Research Center
The Catholic University of America